Amphastar Pharmaceuticals, Inc. (FRA:29A)

Market Cap	1.04B
Revenue (ttm)	616.47M
Net Income (ttm)	95.14M
Shares Out	n/a
EPS (ttm)	1.93
PE Ratio	10.96
Forward PE	7.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	22.05
Previous Close	21.69
Day's Range	22.05 - 22.05
52-Week Range	17.24 - 37.54
Beta	n/a
RSI	50.77
Earnings Date	Feb 27, 2026

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emer...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 2,028
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 29A

Financial Performance

In 2024, Amphastar Pharmaceuticals's revenue was $731.97 million, an increase of 13.59% compared to the previous year's $644.40 million. Earnings were $159.52 million, an increase of 15.98%.

Financial numbers in USD